ATE539062T1 - Bizyklishe verbindung, ihre herstellung und verwendung - Google Patents

Bizyklishe verbindung, ihre herstellung und verwendung

Info

Publication number
ATE539062T1
ATE539062T1 AT10150963T AT10150963T ATE539062T1 AT E539062 T1 ATE539062 T1 AT E539062T1 AT 10150963 T AT10150963 T AT 10150963T AT 10150963 T AT10150963 T AT 10150963T AT E539062 T1 ATE539062 T1 AT E539062T1
Authority
AT
Austria
Prior art keywords
bizyclic
compound
production
bizyclic compound
Prior art date
Application number
AT10150963T
Other languages
English (en)
Inventor
Mitsuru Shiraishi
Masanori Baba
Katsuji Aikawa
Naoyuki Kanzaki
Masaki Seto
Yuji Iizawa
Original Assignee
Tobira Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tobira Therapeutics Inc filed Critical Tobira Therapeutics Inc
Application granted granted Critical
Publication of ATE539062T1 publication Critical patent/ATE539062T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D225/00—Heterocyclic compounds containing rings of more than seven members having one nitrogen atom as the only ring hetero atom
    • C07D225/04—Heterocyclic compounds containing rings of more than seven members having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D225/06—Heterocyclic compounds containing rings of more than seven members having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D313/00—Heterocyclic compounds containing rings of more than six members having one oxygen atom as the only ring hetero atom
    • C07D313/16—Eight-membered rings
    • C07D313/20—Eight-membered rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • Virology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • AIDS & HIV (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Transplantation (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
AT10150963T 2001-08-08 2002-08-07 Bizyklishe verbindung, ihre herstellung und verwendung ATE539062T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2001240750 2001-08-08
JP2002066809 2002-03-12

Publications (1)

Publication Number Publication Date
ATE539062T1 true ATE539062T1 (de) 2012-01-15

Family

ID=26620186

Family Applications (2)

Application Number Title Priority Date Filing Date
AT02762751T ATE460406T1 (de) 2001-08-08 2002-08-07 Bicyclische verbindung, deren herstellung und verwendung
AT10150963T ATE539062T1 (de) 2001-08-08 2002-08-07 Bizyklishe verbindung, ihre herstellung und verwendung

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AT02762751T ATE460406T1 (de) 2001-08-08 2002-08-07 Bicyclische verbindung, deren herstellung und verwendung

Country Status (13)

Country Link
US (7) US7371772B2 (de)
EP (3) EP1889839B1 (de)
JP (4) JP4316203B2 (de)
AR (1) AR034985A1 (de)
AT (2) ATE460406T1 (de)
AU (1) AU2002328092A1 (de)
CA (2) CA2459172C (de)
DE (1) DE60235632D1 (de)
DK (2) DK1423376T3 (de)
ES (2) ES2339340T3 (de)
PE (1) PE20030329A1 (de)
PT (2) PT2206702E (de)
WO (1) WO2003014105A1 (de)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003014105A1 (en) * 2001-08-08 2003-02-20 Takeda Chemical Industries, Ltd. Bicyclic compound, production and use as hiv inhibitors
CA2479071A1 (en) * 2002-03-12 2003-09-18 Hiroyuki Tawada Process for producing optically active sulfoxide derivative
US7288654B2 (en) 2003-02-07 2007-10-30 Takeda Pharmaceutical Company Ltd Fused-ring pyridine derivative, process for producing the same, and use
US20060178359A1 (en) * 2003-02-07 2006-08-10 Mitsuru Shiraishi Tricyclic compound, process for producing the same, and use
US20060160864A1 (en) * 2003-02-07 2006-07-20 Mitsuru Shiraishi Acrylamide derivative, process for producing the same, and use
ES2425937T3 (es) * 2004-03-24 2013-10-18 Takeda Pharmaceutical Company Limited Estabilizante de emulsión
EP1728505B1 (de) * 2004-03-24 2014-06-04 Takeda Pharmaceutical Company Limited Zubereitung mit erhöhtem gehalt
US20050260139A1 (en) * 2004-03-30 2005-11-24 Boehringer Ingelheim International Gmbh Pharmaceutical compositions based on anticholinergics and CCR2 receptor antagonists
JP2007269628A (ja) * 2004-05-28 2007-10-18 Takeda Chem Ind Ltd 医薬化合物の結晶
WO2006059716A1 (ja) * 2004-12-03 2006-06-08 Takeda Pharmaceutical Company Limited 固形製剤
US8426387B2 (en) * 2006-03-31 2013-04-23 Stephen Carper Treatments for cancer
WO2008030853A2 (en) * 2006-09-06 2008-03-13 Incyte Corporation Combination therapy for human immunodeficiency virus infection
TWI499414B (zh) 2006-09-29 2015-09-11 Lexicon Pharmaceuticals Inc 鈉與葡萄糖第２型共同運輸體（ｃｏ-ｔｒａｎｓｐｏｒｔｅｒ ２）的抑制物與其應用方法
US7846945B2 (en) * 2007-03-08 2010-12-07 Lexicon Pharmaceuticals, Inc. Piperdine-based inhibitors of sodium glucose co-transporter 2 and methods of their use
AU2009305619B2 (en) * 2008-10-17 2012-06-21 Invasc Therapeutics, Inc. Compositions and methods for treatment of renin-angiotensin aldosterone system (RAAS)-related disorders
MX381242B (es) 2009-11-27 2025-03-12 Genzyme Corp Una forma amorfa y una cristalina de hemitartrato de genz 112638 como inhibidor de glucosilceramida sintasa.
CA2794443A1 (en) 2010-04-02 2011-10-06 Phivco-1 Llc Combination therapy comprising a ccr5 antagonist, a hiv-1 protease inhibitor and a pharmacokinetic enhancer
WO2012047630A2 (en) * 2010-09-27 2012-04-12 Martin Teintze N-alkyl or n-aryl substituted guanide and biguanide compounds and methods of their use
US20140271680A1 (en) 2011-08-12 2014-09-18 Universite Paris-Est Creteil Val De Marne Methods and pharmaceutical compositions for treatment of pulmonary hypertension
KR20160132489A (ko) 2014-03-21 2016-11-18 토비라 쎄라퓨틱스, 인크. 섬유증 치료용 세니크리바이록
EP3148538A4 (de) * 2014-06-02 2018-01-17 Tobira Therapeutics, Inc. Cenicriviroc zur behandlung einer hiv-2-infektion
US20170319548A1 (en) 2014-09-12 2017-11-09 Tobira Therapeutics, Inc. Cenicriviroc combination therapy for the treatment of fibrosis
US10526349B2 (en) * 2014-12-23 2020-01-07 Tobira Therapeutics, Inc. Process of making cenicriviroc and related analogs
US20180110754A1 (en) 2015-02-10 2018-04-26 Tobira Therapeutics, Inc. Cenicriviroc for the treatment of fibrosis
KR101938036B1 (ko) * 2015-04-16 2019-01-14 서울대학교산학협력단 고혈압 치료제를 이용한 흡연 및 비흡연자의 폐암 억제 방법
MX2018015871A (es) 2016-06-21 2019-08-14 Tobira Therapeutics Inc Cenicriviroc purificado e intermedios purificados para fabricar cenicriviroc.
CN110167550A (zh) 2016-08-31 2019-08-23 妥必徕疗治公司 西克里维罗甲磺酸盐的固体形式及其制备方法
ES2906992T3 (es) * 2016-12-09 2022-04-21 Medshine Discovery Inc Compuesto de bifenilo como antagonista del receptor CCR2/CCR5
CN110418641A (zh) 2017-02-24 2019-11-05 基恩菲特公司 用于组合疗法的药物组合物
CN111630047B (zh) * 2018-02-02 2023-05-23 四川科伦博泰生物医药股份有限公司 含有羧酸基团的苯并氮杂环类化合物及其制备方法和用途
US11666888B2 (en) 2018-02-05 2023-06-06 Bio-Rad Laboratories, Inc. Chromatography resin having an anionic exchange-hydrophobic mixed mode ligand
WO2019238041A1 (zh) * 2018-06-12 2019-12-19 南京明德新药研发有限公司 一种丙烯酰胺类化合物的晶型及其制备方法
CN113412261A (zh) * 2019-04-08 2021-09-17 四川科伦博泰生物医药股份有限公司 苯并咪唑化合物、其制备方法及其用途
WO2020259620A1 (zh) 2019-06-24 2020-12-30 南京明德新药研发有限公司 作为ccr2/ccr5拮抗剂的杂环烷基类化合物
WO2021133811A1 (en) 2019-12-26 2021-07-01 Teva Pharmaceuticals International Gmbh Solid state forms of cenicriviroc and process for preparation thereof
US11629196B2 (en) 2020-04-27 2023-04-18 Incelldx, Inc. Method of treating SARS-CoV-2-associated hypercytokinemia by administering a human monoclonal antibody (PRO-140) that inhibits CCR5/CCL5 binding interactions
CA3179593A1 (en) * 2020-05-22 2021-11-25 Yunfu Luo Pyridine derivative and application thereof
CN112472678A (zh) * 2020-11-12 2021-03-12 澳美制药厂有限公司 肾素那敏制剂及其制备方法
WO2023143112A1 (zh) * 2022-01-26 2023-08-03 无锡瓴方生物医药科技有限公司 氮杂苯并八元环化合物的盐型、晶型及其应用
CN118987211B (zh) * 2023-05-22 2025-09-19 无锡瓴方生物医药科技有限公司 一种联合用药物组合物及其应用

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS62265270A (ja) 1986-05-13 1987-11-18 Zeria Shinyaku Kogyo Kk 新規イミダゾ−ル誘導体およびそれらを有効成分とする抗潰瘍剤
DE69520360T2 (de) 1994-07-04 2001-08-09 Takeda Chemical Industries, Ltd. Phosphonsäure verbindungen imre herstellung und verwendung
RU2167649C2 (ru) 1995-08-11 2001-05-27 Ниссан Кемикал Индастриз, Лтд. Способ получения твердой дисперсии умеренно водорастворимого лекарственного вещества (варианты) и фармацевтическая композиция
US6297244B1 (en) 1997-10-20 2001-10-02 Dainippon Pharmaceutical Co., Ltd. Stable drug composition
WO1999032100A2 (en) * 1997-12-19 1999-07-01 Takeda Chemical Industries, Ltd. Pharmaceutical composition for antagonizing ccr5 comprising anilide derivative
AU5301599A (en) * 1998-08-20 2000-03-14 Takeda Chemical Industries Ltd. Quaternary ammonium salts and their use
CA2244097A1 (en) 1998-08-21 2000-02-21 Bernard Charles Sherman Pharmaceutical composition comprising bupropion hydrochloride and fumaric acid
WO2000037455A1 (en) 1998-12-21 2000-06-29 Takeda Chemical Industries, Ltd. Benzothiepin-anilide derivatives, their production and their use for antagonizing ccr-5
WO2000061109A1 (fr) 1999-04-12 2000-10-19 Shionogi & Co., Ltd. Procede de production de composition medicamenteuse renfermant un compose medicamenteux hydrophobe basique
JP2001026586A (ja) 1999-05-07 2001-01-30 Takeda Chem Ind Ltd 環状化合物およびその用途
EP1211239A4 (de) 1999-09-06 2003-08-06 Takeda Chemical Industries Ltd Verfahren zur herstellung von 2,3-dihydroazepin-derivaten
WO2003014105A1 (en) * 2001-08-08 2003-02-20 Takeda Chemical Industries, Ltd. Bicyclic compound, production and use as hiv inhibitors
CA2479071A1 (en) 2002-03-12 2003-09-18 Hiroyuki Tawada Process for producing optically active sulfoxide derivative
ES2425937T3 (es) * 2004-03-24 2013-10-18 Takeda Pharmaceutical Company Limited Estabilizante de emulsión
EP1728505B1 (de) * 2004-03-24 2014-06-04 Takeda Pharmaceutical Company Limited Zubereitung mit erhöhtem gehalt
WO2006059716A1 (ja) 2004-12-03 2006-06-08 Takeda Pharmaceutical Company Limited 固形製剤
WO2008030853A2 (en) 2006-09-06 2008-03-13 Incyte Corporation Combination therapy for human immunodeficiency virus infection
CA2794443A1 (en) 2010-04-02 2011-10-06 Phivco-1 Llc Combination therapy comprising a ccr5 antagonist, a hiv-1 protease inhibitor and a pharmacokinetic enhancer
US9562038B2 (en) 2010-11-18 2017-02-07 Yale University Bifunctional molecules with antibody-recruiting and entry inhibitory activity against the human immunodeficiency virus
JP6178788B2 (ja) 2011-06-27 2017-08-09 ウニヴェルシテ ピエール エ マリー キュリー（パリ ６） Ｃｃｒ２アンタゴニストペプチド
JP6391674B2 (ja) 2013-05-15 2018-09-19 トビラ セラピューティクス， インコーポレイテッド セニクリビロック組成物並びにその製造及び使用方法
KR20160132489A (ko) 2014-03-21 2016-11-18 토비라 쎄라퓨틱스, 인크. 섬유증 치료용 세니크리바이록
US10526349B2 (en) 2014-12-23 2020-01-07 Tobira Therapeutics, Inc. Process of making cenicriviroc and related analogs
US20180110754A1 (en) 2015-02-10 2018-04-26 Tobira Therapeutics, Inc. Cenicriviroc for the treatment of fibrosis

Also Published As

Publication number Publication date
EP2206702B1 (de) 2011-12-28
ES2376855T3 (es) 2012-03-20
US20090030032A1 (en) 2009-01-29
US20160008326A1 (en) 2016-01-14
JP5275148B2 (ja) 2013-08-28
JP2013136629A (ja) 2013-07-11
JP2003335776A (ja) 2003-11-28
WO2003014105A1 (en) 2003-02-20
PT1423376E (pt) 2010-04-12
PT2206702E (pt) 2012-02-03
JP2007084578A (ja) 2007-04-05
US10045968B2 (en) 2018-08-14
EP1423376B1 (de) 2010-03-10
US7371772B2 (en) 2008-05-13
DK2206702T3 (da) 2012-02-13
JP4316203B2 (ja) 2009-08-19
US8362058B2 (en) 2013-01-29
AR034985A1 (es) 2004-03-24
DE60235632D1 (de) 2010-04-22
US8741943B2 (en) 2014-06-03
CA2607992A1 (en) 2003-02-20
PE20030329A1 (es) 2003-05-12
AU2002328092A1 (en) 2003-02-24
DK1423376T3 (da) 2010-06-28
CA2459172A1 (en) 2003-02-20
EP1423376A1 (de) 2004-06-02
JP2009209154A (ja) 2009-09-17
EP2206702A1 (de) 2010-07-14
US20040259876A1 (en) 2004-12-23
US8183273B2 (en) 2012-05-22
CA2459172C (en) 2011-07-05
JP4358851B2 (ja) 2009-11-04
US20120232028A1 (en) 2012-09-13
ATE460406T1 (de) 2010-03-15
WO2003014105A9 (en) 2003-11-20
EP1889839A1 (de) 2008-02-20
US20080161287A1 (en) 2008-07-03
EP1889839B1 (de) 2013-11-06
ES2339340T3 (es) 2010-05-19
HK1142886A1 (en) 2010-12-17
US20190038604A1 (en) 2019-02-07
US20200297700A1 (en) 2020-09-24

Similar Documents

Publication Publication Date Title
ATE539062T1 (de) Bizyklishe verbindung, ihre herstellung und verwendung
ATE424202T1 (de) Substituierte 2-thio-3,5-dicyano-4-phenyl-6- aminopyridine und ihre verwendung
DE50207849D1 (de) Substituierte 2-oxy-3,5-dicyano-4-aryl-6-aminopyridine und ihre verwendung
EP1417988A4 (de) Atemgerät
CY2014041I2 (el) 2,3-διυδρο-6-νιτροϊμιδαζο 2,1 -b-οξαζολια
DE60008862D1 (de) Thienopyrimidin verbindungen, ihre herstellung und verwendung
DE60200427D1 (de) Vernetzbare Fluorelastomerzusammensetzungen, ihre Herstellung und Verwendung
DE60235547D1 (de) En daraus, deren herstellung und verwendung
DE60221403D1 (de) Doppelstrom - verdichter
ATE265454T1 (de) Phenyloxazol-1,4-diazabicyclo(3.2.2)nonanderiva e,ihre herstellung und ihre therapeutische verwendung
ATE533768T1 (de) Imidazol-derivate, ihre herstellung und ihre verwendung
DE60334632D1 (de) Mechanolumineszenzstoff und dessen herstellung
ATE392418T1 (de) Substituierte fluoralkoxyphenylsulfonylharnstoffe
ATE396994T1 (de) 3-phenylpyridoindolderivate, ihre herstellung und verwendung
BR0104888B1 (pt) compressor.
EP1445094A4 (de) Lichtschutzfolie
ATE505459T1 (de) Dibenzoäb,füazepin-derivate und ihre herstellung
NO20040665L (no) Produksjon av hydrokarboner.
DZ3441A1 (fr) Nouvelles phenylpiperazines.
DE60213827D1 (de) Antikörper gegen Caspase-8, ihre Herstellung und Verwendung
DE60207451D1 (de) Produktionsverfahren
DE60216321D1 (de) 3-heteroaryl-3,5-dihydro-4-oxo-4h-pyridazinoä4,5-büindol-1-karboxamid-derivate, ihre herstellung und therapeutische verwendung
EE200300564A (et) Püridüülmetüülaminopürimidiiniühendid, nende kasutamine ja ravim
IS7131A (is) Nýjar 2,4-díamínóþíasól afleiður
DK1497256T3 (da) Substituerede 1,5-diaminopentan-3-ol-forbindelser